Source: BioSpace
Area: News
According to BioSpace, the European Commission has approved ocriplasmin (Jetrea®) for the treatment of vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns. This follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued in January 2013 (please see a related NeLM report via the link below for further details, including a discussion of the available efficacy data and the drug's mechanism of action).
Uncategorized